Anti-thrombotic methods include intravenous thrombolytic therapy, anti-platelet aggregation therapy and anticoagulation therapy, as follows: 1. intravenous thrombolytic therapy: use of alteplase or urokinase thrombolysis, requiring patients to be within the thrombolytic time window from the onset to the consultation, alteplase requires within 4.5 hours, and urokinase requires within 6 hours, and can only be used after excluding contraindications; 2. anti-platelet aggregation therapy: use of Aspirin or clopidogrel, both have similar effects, but aspirin tends to cause increased secretion of gastric acid and may induce ulcers, while clopidogrel has no such side effects; 3, anticoagulation therapy: use warfarin, which is more troublesome to use and requires regular monitoring of INR, the international standard ratio, to maintain this ratio between 2 and 3, in order to enable patients to have anticoagulation effects while without causing a strong risk of bleeding. A similar anticoagulant, rivaroxaban, does not require monitoring of the blood PT series and the INR, but has the disadvantage of being expensive.